Trial Profile
Plasma Anti-FXa Concentration After Continuous Intravenous Infusion and Subcutaneous Dosing of Enoxaparin for Thromboprophylaxis in Critically Ill Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Enoxaparin sodium (Primary)
- Indications Venous thromboembolism
- Focus Pharmacokinetics
- 26 Oct 2017 Status changed from recruiting to completed.
- 24 Jan 2013 New trial record